CH426808A - Process for the preparation of new piperidine derivatives - Google Patents
Process for the preparation of new piperidine derivativesInfo
- Publication number
- CH426808A CH426808A CH932463A CH932463A CH426808A CH 426808 A CH426808 A CH 426808A CH 932463 A CH932463 A CH 932463A CH 932463 A CH932463 A CH 932463A CH 426808 A CH426808 A CH 426808A
- Authority
- CH
- Switzerland
- Prior art keywords
- radical
- acid
- hydrogen
- carbon atoms
- piperidyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000003053 piperidines Chemical class 0.000 title claims description 4
- -1 alkyl radical Chemical class 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229910052753 mercury Inorganic materials 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- RMCDUNHIVVEEDD-UHFFFAOYSA-N methylcyclopropane Chemical compound [CH2]C1CC1 RMCDUNHIVVEEDD-UHFFFAOYSA-N 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 5
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 4
- DOBUSJIVSSJEDA-UHFFFAOYSA-L 1,3-dioxa-2$l^{6}-thia-4-mercuracyclobutane 2,2-dioxide Chemical compound [Hg+2].[O-]S([O-])(=O)=O DOBUSJIVSSJEDA-UHFFFAOYSA-L 0.000 description 3
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical group O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910000370 mercury sulfate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002902 organometallic compounds Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical group O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PYJVGTWBTIEAMV-UHFFFAOYSA-N 3-bromobut-1-yne Chemical compound CC(Br)C#C PYJVGTWBTIEAMV-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940008718 metallic mercury Drugs 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010653 organometallic reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Description
Verfahren zur Herstellung von neuen Piperidinderivaten
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen P-iperidinderivaten mit wertvollen pharmakologischen Eigenschaften.
Es wurde überraschenderweise gefunden, dass Piperidinderivate der Formel I,
EMI1.1
in welcher Ri Wasserstoff, einen Alkylrest mit höchstens 12
Kohlenstoffatomen, einen Alkenylrest mit 3-5
Kohlenstoffatomen, den Cyclopropylmethylrest oder einen Phenylalkylrest mit 7-9 Kohlenstoff atomen, Ra Wasserstoff oder den Methylrest, R3 Wasserstoff oder einen Alkylrest mit höchstens
3 Kohlenstoffatomen, den Phenylrest, einen
Phenylalkylrest mit 7-8 Kohlenstoffatomen, und R4 Wasserstoff oder den Methylrest bedeutet, und ihre Salze mit anorganischen und organischen Säuren wertvolle pharmakologische Eigenschaften, insbesondere eine ausgezeichnete analgetische Wirksamkeit bei oraler wie parenteraler Applikation und starke antitussive Wirksamkeit besitzen.
Sie sind zugleich relativ wenig toxisch und eignen sich deshalb z. B. zur Linderung und Behebung von Schmerzen verschiedener Genese und auch des Hustenreizes.
In den Verbindungen der Formel I und den zugehörigen, weiter unten genannten Ausgangsstoffen ist Ri z. B. durch Wasserstoff, Alkylreste, wie den Methyl-, Äthyl-, n-Propyl-, Isopropyl-, n-Butyl-, Isobutyl-, sek.-Butyl-, n-Amyl-, Isoamyl-, n-Hexyl-, n-Octyl, n-Decyl-oder n-Dodecyl-rest ; durch Alkenylreste, wie den Allyl-, Crotyl-, Methallyl-oder y, y-Dimethylallylrest ; durch den Cyclopropylmethylrest oder durch Phenyl alkylrestc, wie den
Benzyl-, -Phcnyläthyl-oder y-Phenylpropylrest verkörpert.
R8 ist z. B. Wasserstoff, der Methyl-, Äthyl-, n-Propyl-, Isopropyl-, Phenyl-, Benzyl-, a-Phenyl äthyl-oder ss-Phenyläthyirest
Die Verbindungen der Formel I lassen sich, wie weiter gefunden wurde, in überraschend einfacher Weise herstellen, indem man eine Verbindung der Formel II,
EMI1.2
in welcher Ri, R2, R3 und Ri die oben angegebene Bedeutung haben, mit einer Quecksilberionen enthaltenden wässrigen Mineralsäure bei Raumtempera- tur von mässig erhöhter Temperatur behandelt. Als wässrige Mineralsäure für die Durchführung der Hy dratisierung eignet sich beispielsweise 10-84 % ige Schwefelsäure, ferner kann z.
B. auch etwa 15% ige bis 36% ige (konzentrierte) Salzsäure verwendet werden. Die Reaktionstemperatur wird bei steigender Säurekonzentration niedriger gewählt, bei Verwendung von 84 % iger Schwefelsäure wird die Reaktion vorzugsweise bei Raumtemperatur, mit 10 % iger Schwefelsäure oder etwa 1 : 1 verdünnter Salzsäure bei 50-60 durchgeführt.
Einzelne Vertreter von Ausgangsstoffen der Formel II mit Wasserstoff als R2 und R3 sind in der französischen Patentschrift Nr. 665 M beschrieben, und weitere sind ebenfalls in der dort angegebenen Weise, das heisst durch Umsetzung von Propargylbromid mit amalgamiertem Magnesium, Zink oder Aluminium in einem Gemisch von Tetrahydrofuran und Toluol, und Kondensation der entstandenen metallorganischen Verbindung mit einem entsprechend der Definition von Ri und R4 substituierten 4-Piperidon herstellbar. Anstelle des Propargylbromids können auch analoge Verbindungen, wie z. B. das 3-Brom-l-butin oder das 1-Brom-2-butin, eingesetzt werden, die Ausgangsstoffe der Formel II mit von Wasserstoff verschiedenem Rest R2 und/oder R3 liefern.
Das in der genannten französischen Patentschrift beschriebene Verfahren wird mit Orteil dadurch modifiziert, dass man anstelle von bloss mit Quecksilberchlorid amalgamiertem Aluminiumgries solches verwendet, das zunächst mittels metallischem Quecksilber amalgamiert und hierauf mit Quecksilberchlorid behandelt wurde.
Die Herstellung von Ausgangsstoffen der Formel II, die als Ri ein Wasserstoffatom enthalten, kann z. B. nach dem vorstehend genannten Verfahren unter Verwendung der doppelt molaren Menge Propargylbromid oder eines Analogen und entsprechend erhöhter Metallmenge erfolgen. Die Herstellung von Ausgangsstoffen, welche eine Keto-, Cyano-oder Estergruppierung in Ri enthalten, kann z. B. durch partielle Umsetzung der metallorganischen Verbindungen mit entsprechend substituierten 4-Piperidonen bezüglich deren reaktionsfähigerer, 4ständiger Ketogruppe des Piperidinringes, unter Erhaltung der zweiten reaktionsfähigen Gruppe, erfolgen.
Verwendet man zur Zersetzung des aus der metallorganischen Umsetzung resultierenden Reaktionsgemisches zusammen mit Eis. anstelle der Essigsäure eine Mineralsäure, z. B. konz. Salzsäure, so erhält man eine organische und eine mineralsaure wässrige Phase. Letztere enthält die Reaktionskomponenten für das erfindungsgemässe Verfahren, das heisst die gewünschte Verbindung der Formel II und Quecksilberionen in mineralsaurer, z. B. salzsaurer Lösung, und stellt, sofern durch ein geeignetes Mischungsverhältnis von Eis und Säure, z. B. gleiche Teile Eis und konz. Salzsäure, für eine geeignete Säurekonzentration gesorgt wurde, bereits die Ausgangsmischung für das erfindungsgemässe Verfahren dar, bei deren Erwärmen der Endstoff der Formel I entsteht.
Mit anorganischen und organischen Säuren, wie SalzsäurB Bromwasserstoffsäure, Schwefelsäure,
Salpetersäure, Phosphorsäure, Methansulfonsäure, Äthandisulfonsäure, ss-Hydroxyäthansulfonsäure,
Essigsäure, Propionsäure, Maleinsäure,
Fumarsäure, Milchsäure, Äpfelsäure, Weinsäure,
Citronensäure, Benzoesäure, Salicylsäure,
Phenylessigsäure und Mandelsäure bilden die Verbindungen der Formel I Salze, die teilweise gut wasserlöslich sind.
Die nachfolgenden Beispiele erläutern die Durchführung der erfindungsgemässen Verfahren, stellen jedoch keineswegs die einzigen Ausführungsformen derselben vor. Die Temperaturen sind in Celsius- graden angegeben.
Beispiel 1 a) 4, 05 g Aluminiumgries werden mit 10 g Quecksilber versetzt und mit einem Rührer gut vermischt. Dann wird das unverbrauchte Quecksilber abdekantiert. Das amalgamierte Aluminium wird in 25 ml abs. Tetrahydrofuran und 15 ml abs. Benzol mit 15 mg Quecksilberchlorid kurz aufgekocht und anschliessend 15 Minuten weitergerührt. Hierauf werden bei 50-60 von insgesamt 20, 5 ml Propargylbromid so viel ohne Lösungsmittel zugegeben, bis die Reaktion in Gang kommt und die Temperatur gegen 70 steigt ; nachher wird das restliche Propargylbromid, verdünnt mi't 35 ml abs. Benzol, zugefügt. Das Gemisch wird 30 Minuten gerührt.
Hierauf werden bei 20-25 50 g l- (-Phenyl-äthyl)-4-piperi- don in 150 ml abs. Benzol unter Eiskühlung langsam zugetropft und das Gemisch weitere 15 Stun- den gerührt Dann wird es mit Eis und 2n Salzsäure zersetzt, die wässrige Phase abgetrennt, mit Chloroform gewaschen und mit konz. Natronlauge alkalisch gemacht, und die freigesetzte Base in Chloroform aufgenommen. Die Chloroformlösung wird getrocknet und eingedampft und der Rückstand destilliert, wobei das l-(ss-Phenyl-äthyl) 4 (2'-propinyl) +piperi- dinol vom Kp. 0, 03 130-140 erhalten wird.
Auf analoge Weise erhält man z. B. : l-Benzyl-4-(2'-propinyl)-4-piperidinol,
Kp.0. o3128-135 ;
1-Methyl-4- (2'-propinyl)-4-piperidinol,
Smp. 91-93 ;
1-Methyl-4- (l'-methyl-2'-propinyl)-4-piperidinol,
Kp. o. oi 75-78 ;
1-Äthyl-4-(2'-propinyl)-4-piperdinol ; l-n-Butyl-4-(2'-propinyl)-4-piperidinol ;
1-n-Dodecyl-4-(2'-propinyl)-4-piperidinol ;
1-(1-Methyl-ss-phenyl-äthyl)-4-(2'-propinyl)
4-piperidinol; 1- (y-Phenyl-propyl)-4- (2'-propinyl)-4-piperidinol. b) 5, 3 g 1-(ss-Phenyl-äthyl)-4-(2'-propinyl)-4-pi- peridinol werden mit 21 ml 10SSiger Schwefelsäure und 300 mg Quecksilbersulfat 5 Stunden bei 60 gerührt.
Hierauf wird das Gemisch mit konz. Natronlauge alkalisch gemacht und mit Chloroform extrahiert. Die Chloroformlösung wird mit gesät- tigter Natriumchloridlösung gewaschen, getrocknet und eingedampft. Die Destillation des Rückstandes liefert das l-[l'-(ss-Phenyl-äthyl)-4'-hydroxy-4'-pipe- ridyl]-2-propanon vom Kp. o, or 135-140 .
Das aus einer Lösung der Base in Isopropanol/ Ather mittels ätherischer Chlorwasserstofflösung ausgefällte Hydrochlorid schmilzt nach Umkristallisation aus Isopropanol bei 127-129 .
Auf analoge Weise werden z. B. erhalten :
1- {l'-Benzyl4'-hydroxy-4'-piperidyl)-2-propanon,
Kp. o, oi 130-135 ,
Hydrochlorid Smp. 166-168 ; l-(l'-Methyl-4'-hydroxy-4'-piperidyl)-2-propanon, Kp. o, oi 75 ; Kp. X2125-130 ,
Hydrochlorid Smp. 125-127 (aus Iso propanol), Citrat Smp. 103-105 ;
3-(1'-Methyl-4'-hydroxy-4'-piperidyl)-2-butanon,
Kp. o, oi 78-80 , Citrat Smp. 125-126 ; 1- (1'-Athyl-4.'-hydroxy-4'-piperidyl)-2-propanon ;
1-(1'-n-butyl-4'-hydroxy-4'-piperidyl)-2-propanon ;
1- (l'-n-Dodecyl-4'-hydroxy-4'-piperidyl)-
2-propanon, Kp.0,09 135-138 ; l-[l'-(a-MethylnB-phenyl-äthyl)-4'-hydroxy- 4'-piperidyl]-2-propanon ; 1- [l'- (y-Phenyl-propyl)-4'-hydroxy-4'-piperidyl]-
2-propanon.
Beispiel 2 a) 4, 05 g Aluminiumgries werden mit 10 g Queck- silber versetzt und mit einem Riihrer gut vermischt.
Dann wird das unverbrauchte Quecksilber abdekantiert. Das amalgamierte Aluminium wird in 25 mi absolutem Tetrahydrofuran und 15 ml abs. Benzol mit 15 mg Quecksilberchlorid kurz aufgekocht und anschliessend 15 Minuten, weitergeruhrt. Hierauf werden bei 50-60 von insgesamt 20, 5 ml Propargylbromid so viel Lösungsmittel zugegeben, bis die Reaktion in Gang kommt und die Temperatur gegen 70 steigt ; nachher wird das restliche Propargylbromid, verdünnt mit 35 ml abs. Benzol, zugefügt.
Das Gemisch wird 30 Minuten gerührt. Hierauf werden bei 20-25 50 g 1-(ss-Phenyl-äthyl)-4-piperidon in 150 ml abs. Benzol unter Eiskühlung zugetropft und das Gemisch weitere 15 Stunden gerührt. Dann wird das Reaktionsgemisch mit etwa 150 g Eis und 150 ml konz. Salzsäure zersetzt und die Benzolphase abgetrennt. b) Die erhaltene salzsaure Lösung wird 4-6 Stunden bei 40-60 gerührt. Dann wird sie mit Chloroform gewaschen, mit konz. Natronlauge alkalisch gemacht und mit Chloroform extrahiert.
Die Chloroformlösung wird getrocknet und eingedampft und der Rückstand destilliert, wobei das 1- [1'- (-Phenyl-athyl)-4'-hydroxy-4'-piperidyl]-
2-propanon vom Kp. o, oi 135-140 erhalten wird.
Analog zur Arbeitsweise von Beispiel 1 oder 2 können z. B. auch folgende Verbindungen erhalten werden :
1-(1'-Merthyl-4'-hdyroxy'-4-piperidyl)-2-butanon,
Kp. o, 0195 , Citrat Smp. 145-146 ; 1- (l'-Methyl-4'-hydroxy-4'-piperidyl)-2-pentanon, KP. o, oos 119-121 , Citrat Smp. 126-128 ;
1-(1'-Methyl-4'-hydroxy-4'-piperidyl)-2-hexanon, Kp. o, or 11g118 ;
1-(1'-Methyl-4'-hydroxy-4'-piperidyl)-3-phneyl
2-propanon, Kp. 0, 003 132-135 ;
2-(1'-Methyl-4'-hydroxy-4'-piperidyl)-3-pentanon,
Kp. o, 008 95-100 , Citrat 130-132 ;
1-(1'-n-Propyl-4'-hydroxy-4'-piperidyl)
2-propanon, Kp. 0, 01 80-82 , Hydrochlorid
Smp. 137-139 .
Beispiel 3 a) 12 g fein gepulvertes Hydrochlorid des 4-Piperidinols werden zu 20 g fein gepulvertem Natriumhydroxyd in 80 ml Chloroform bei-20 zugegeben.
Dann werden langsam 2 ml Wasser zugegeben, worauf die Temperatur steigt. Durch Kühlen wird dafür gesorgt, dass sie nicht über 10 steigt.
Dann wird Natriumsulfat zugegeben, das Reak tionsgemisch filtriert und das Filtrat im Rotations verdampfer eingedampft, zuletzt für 5 Minuten unter Hochvakuum, wobei das 4-Piperidinol zurück- bleibt. 9 g Magnesium werden in 20 ml abs. Ather vorgelegt, 0, 1 g Quecksilberchlorid zugegeben und bei-10 bis-5 44, 5 g APropargylbromid in 100 ml abs. Ather zugetropft. Anschliessend wird noch 20 Minuten bei-5 weitergerührt. Bei-5 bis 0 werden hierauf 28, 95 g 4-Piperidinol in 250 ml abs.
Benzol zugetropft, wobei sich das Reaktionsgemisch erwärmt. Es wird 30 Minuten bei 0 und anschlie- ssend etwa 14 Stunden bei Raumtemperatur weitergerührt. Hierauf gibt man Eis und Eisessig zu, trennt die Benzolphase ab und extrahiert sie mit 2n Essigsäure. Die essigsauren Lösungen werden vereinigt, mit Ather geschüttelt und hierauf alkalisch gestellt.
Die freigesetzte Base wird mit Chloroform extrahiert, die Chloroformlösung getrocknet und eingedampft, wobei 9, 3 g eines Öls zurückbleiben. Die Destillation liefert ein 61 vom Kp. o, 05 100-140 (Luftbad), das kristallisiert. Das so erhaltene 4- (2'-Propinyl)-4- piperidinol schmilzt bei 76-78 . b) 1, 6 g des Produktes von a) werden mit 16 ml 2n Schwefelsäure und 200 mg Quecksilbersulfat 3 Stunden bei Raumtemperatur stehengelassen. Das Reaktionsgemisch wird alkalisch gestellt und mit Chloroform ausgezogen, die Chloroformlösung getrocknet und eingedampft.
Der Rückstand wird im Kugelrohr destilliert, wobei das 1-(4'-Hydroxy 4'-piperidyl)-2-propanon erhalten wird, Kp. o, ot 70 , Smp. 98-100 .
Beispiel 4 a) In einem Sulfierkolben werden 15, 35 g 4-Pi peridon-Hydrat-Hydrochlorid in 110 ml ln Natrium bicarbonatlosung gelöst. Unter Kiihlung und Vibrie ren werden bei 5-10 17, 1 g Benzyloxycarbonylchlorid und 110 ml ln Natriumbicarbonadösung so zutropfen gelassen, dass das Reaktionsgemisch immer alkalisch bleibt. Anschliessend wird es während 1% Stunden weiter vibriert und die entstandene milchige Emulsion mit Ather ausgezogen. Die Atherlösung wird zweimal mit 2n Salzsäure und dann zweimal mit gesättigter Natriumchloridlosung durchgeschüttelt, getrocknet und eingedampft und der Rückstand im Hochvakuum destilliert.
Das 1-Benzyloxycarbo- nyl-4-piperidon siedet bei 125-131 /0,004 Torr. b) In einem Rührkolben werden 4 g Magnesium in 6 ml abs. Ather vorgelegt und dann unter Rühren zwischen 10-15 19, 5 g Propargylbromid in 35 ml abs. Ather zutropfen gelassen. Anschliessend werden 19, 1 g 1-Benzyloxycarbonyl-4-piperidon in 80 ml abs. Benzol bei 2U-25 langsam zugetropft, wobei sich ein Klumpen bildet, der sich aber beim weiteren Rühren wieder löst. Hierauf wird das Reaktionsgemisch weitere 3 Stunden gerührt. Dann wird es mit Eis und 2n Schwefelsäure zersetzt und-mit Ather ausgezogen.
Die Atherlösung wird mit 2n Schwefelsäure gut durchgeschüttelt, getrocknet und einge- dampft. Das zurückbleibende 1-Benzyloxycarbonyl- 4-(2'-propinyl) +piperidinol siedet bei 160-163 / 0, 01 Torr. c) 50 g 1-Benzyloxycarbonyl-4-(2'-propinyl)-4 piperidinol werden in einem Gemisch von 500 ml 20 % iger Schwefelsare und 350 ml Dioxan, das 5 g Quecksilbersulfat enthält, 1 Stunde auf 35-40 erwärmt. Hierauf wird das Dioxan im Vakuum abge- dampft, der Rückstand mit Chloroform ausgezogen, das Chloroformextrakt mit gesättigter Natriumchlo- ridlösung gewaschen, getrocknet und eingedampft.
Bei der Destillation des Rückstandes erhält man das
1-(1'-Benzyloxycarbonyl-4'-hydroxy-4'-piperidyl)
2-propanon vom Kp. 0, 03 180-190 C. d) 30, 8 g (1-(1'-benzyloxycarbonyl-4'-hydroxy-4' piperidyl)-2-propanon werden in 350 ml Äthanol gelöst und in Gegenwart von 3 g und später weiteren 1, 5 g 5 % iger Palladiumkohle Wasserstoff durchgeleitet, bis kein Kohlendioxyd mehr nachgewiesen werden kann (etwa 5 Stunden). Dann wird der Katalysator abfiltriert, die Lösung eingedampft, der Rückstand in Methylenchlorid aufgenommen, die Lösung getrocknet und eingedampft und der Rückstand im Hochvakuum destilliert. Das 1- (4'-Hydroxy-4'-piperi dyl)-2-propanon geht unter 0, 01 Torr bei 80-100 Luftbadtemperatur unter teilweiser Zersetzung über Smp. 98-100 , vgl. Beispiel 3.
Process for the preparation of new piperidine derivatives
The present invention relates to a process for the preparation of new P-iperidine derivatives with valuable pharmacological properties.
It has surprisingly been found that piperidine derivatives of the formula I,
EMI1.1
in which Ri is hydrogen, an alkyl radical with at most 12
Carbon atoms, an alkenyl radical with 3-5
Carbon atoms, the cyclopropylmethyl radical or a phenylalkyl radical with 7-9 carbon atoms, Ra is hydrogen or the methyl radical, R3 is hydrogen or an alkyl radical with at most
3 carbon atoms, the phenyl radical, one
Phenylalkyl radical with 7-8 carbon atoms, and R4 denotes hydrogen or the methyl radical, and their salts with inorganic and organic acids have valuable pharmacological properties, in particular excellent analgesic effectiveness in oral and parenteral administration and strong antitussive effectiveness.
At the same time, they are relatively less toxic and are therefore suitable for. B. to relieve and eliminate pain of various origins and also the cough stimulus.
In the compounds of formula I and the associated starting materials mentioned below, Ri is z. B. by hydrogen, alkyl radicals, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, n-amyl, isoamyl, n-hexyl, n-octyl, n-decyl or n-dodecyl radical; by alkenyl radicals, such as the allyl, crotyl, methallyl or y, y-dimethylallyl radical; by the Cyclopropylmethylrest or by Phenyl alkylrestc, like the
Benzyl, -Phcnyläthyl- or γ-Phenylpropylrest embodied.
R8 is e.g. B. hydrogen, the methyl, ethyl, n-propyl, isopropyl, phenyl, benzyl, a-phenyl ethyl or ss-phenylethyl radical
As has also been found, the compounds of the formula I can be prepared in a surprisingly simple manner by adding a compound of the formula II,
EMI1.2
in which Ri, R2, R3 and Ri have the meaning given above, treated with an aqueous mineral acid containing mercury ions at room temperature of moderately elevated temperature. As an aqueous mineral acid for performing the Hy dratisierung is, for example, 10-84% sulfuric acid, further z.
B. about 15% to 36% (concentrated) hydrochloric acid can be used. The reaction temperature is chosen to be lower with increasing acid concentration; when using 84% sulfuric acid, the reaction is preferably carried out at room temperature, with 10% sulfuric acid or approximately 1: 1 dilute hydrochloric acid at 50-60.
Individual representatives of starting materials of the formula II with hydrogen as R2 and R3 are described in French patent specification No. 665 M, and others are also in the manner indicated there, that is, by reacting propargyl bromide with amalgamated magnesium, zinc or aluminum in a mixture of tetrahydrofuran and toluene, and condensation of the organometallic compound formed with a 4-piperidone substituted according to the definition of Ri and R4. Instead of the propargyl bromide, analog compounds, such as. Example, 3-bromo-1-butyne or 1-bromo-2-butyne can be used, which supply starting materials of the formula II with a radical R2 and / or R3 other than hydrogen.
The method described in the French patent specification mentioned is modified with Orteil by using instead of aluminum grit amalgamated merely with mercury chloride, which was first amalgamated with metallic mercury and then treated with mercury chloride.
The preparation of starting materials of the formula II which contain a hydrogen atom as Ri can, for. B. be carried out by the above-mentioned method using twice the molar amount of propargyl bromide or an analog and a correspondingly increased amount of metal. The preparation of starting materials which contain a keto, cyano or ester group in Ri can, for. B. by partial reaction of the organometallic compounds with appropriately substituted 4-piperidones with respect to their more reactive, 4-position keto group of the piperidine ring, while maintaining the second reactive group.
It is used to decompose the reaction mixture resulting from the organometallic reaction together with ice. instead of acetic acid, a mineral acid, e.g. B. conc. Hydrochloric acid, an organic and a mineral acid aqueous phase are obtained. The latter contains the reaction components for the process according to the invention, that is to say the desired compound of formula II and mercury ions in mineral acid, e.g. B. hydrochloric acid solution, and if provided by a suitable mixing ratio of ice and acid, z. B. equal parts ice and conc. Hydrochloric acid, if a suitable acid concentration has been ensured, is already the starting mixture for the process according to the invention, the end product of the formula I being formed when it is heated.
With inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid,
Nitric acid, phosphoric acid, methanesulphonic acid, ethane disulphonic acid, ss-hydroxyethanesulphonic acid,
Acetic acid, propionic acid, maleic acid,
Fumaric acid, lactic acid, malic acid, tartaric acid,
Citric acid, benzoic acid, salicylic acid,
Phenylacetic acid and mandelic acid form the compounds of the formula I salts, some of which are readily soluble in water.
The following examples explain the implementation of the process according to the invention, but by no means represent the only embodiments thereof. The temperatures are given in degrees Celsius.
Example 1 a) 4.05 g of aluminum powder are mixed with 10 g of mercury and mixed well with a stirrer. Then the unused mercury is decanted off. The amalgamated aluminum is in 25 ml abs. Tetrahydrofuran and 15 ml of abs. Benzene briefly boiled with 15 mg of mercury chloride and then stirred for a further 15 minutes. Then at 50-60 of a total of 20.5 ml of propargyl bromide are added without solvent until the reaction starts and the temperature rises to 70; then the remaining propargyl bromide is diluted with 35 ml abs. Benzene, added. The mixture is stirred for 30 minutes.
Then at 20-25 50 g of l- (-phenyl-ethyl) -4-piperidone in 150 ml of abs. Benzene is slowly added dropwise while cooling with ice and the mixture is stirred for a further 15 hours. Then it is decomposed with ice and 2N hydrochloric acid, the aqueous phase is separated off, washed with chloroform and concentrated with conc. Sodium hydroxide solution made alkaline, and the released base was taken up in chloroform. The chloroform solution is dried and evaporated and the residue is distilled, whereby the 1- (ss-phenyl-ethyl) 4 (2'-propynyl) + piperidinol of boiling point 0.03 130-140 is obtained.
In an analogous way one obtains z. B.: l-Benzyl-4- (2'-propynyl) -4-piperidinol,
Kp.0. o3128-135;
1-methyl-4- (2'-propynyl) -4-piperidinol,
M.p. 91-93;
1-methyl-4- (l'-methyl-2'-propynyl) -4-piperidinol,
Bp. O. Oi 75-78;
1-ethyl-4- (2'-propynyl) -4-piperdinol; 1-n-butyl-4- (2'-propynyl) -4-piperidinol;
1-n-dodecyl-4- (2'-propynyl) -4-piperidinol;
1- (1-methyl-ss-phenyl-ethyl) -4- (2'-propynyl)
4-piperidinol; 1- (γ-phenyl-propyl) -4- (2'-propynyl) -4-piperidinol. b) 5.3 g of 1- (ß-phenyl-ethyl) -4- (2'-propynyl) -4-piperidinol are stirred with 21 ml of 10% sulfuric acid and 300 mg of mercury sulfate at 60 for 5 hours.
The mixture is then concentrated with. Sodium hydroxide solution made alkaline and extracted with chloroform. The chloroform solution is washed with saturated sodium chloride solution, dried and evaporated. Distillation of the residue yields the 1- [l '- (ss-phenyl-ethyl) -4'-hydroxy-4'-piperidyl] -2-propanone of bp o, or 135-140.
The hydrochloride precipitated from a solution of the base in isopropanol / ether by means of an ethereal hydrogen chloride solution melts at 127-129 after recrystallization from isopropanol.
In an analogous way z. B. received:
1- {l'-Benzyl4'-hydroxy-4'-piperidyl) -2-propanone,
Kp. O, oi 130-135,
Hydrochloride m.p. 166-168; 1- (l'-methyl-4'-hydroxy-4'-piperidyl) -2-propanone, b.p. o, oi 75; Kp. X2125-130,
Hydrochloride m.p. 125-127 (from isopropanol), citrate m.p. 103-105;
3- (1'-methyl-4'-hydroxy-4'-piperidyl) -2-butanone,
B.p. o, oi 78-80, citrate m.p. 125-126; 1- (1'-ethyl-4'-hydroxy-4'-piperidyl) -2-propanone;
1- (1'-n-butyl-4'-hydroxy-4'-piperidyl) -2-propanone;
1- (l'-n-dodecyl-4'-hydroxy-4'-piperidyl) -
2-propanone, b.p. 0.09 135-138; 1- [l '- (a-MethylnB-phenyl-ethyl) -4'-hydroxy-4'-piperidyl] -2-propanone; 1- [l'- (y-phenyl-propyl) -4'-hydroxy-4'-piperidyl] -
2-propanone.
Example 2 a) 4.05 g of aluminum powder are mixed with 10 g of mercury and mixed well with a stirrer.
Then the unused mercury is decanted off. The amalgamated aluminum is dissolved in 25 ml of absolute tetrahydrofuran and 15 ml of abs. Benzene briefly boiled with 15 mg mercury chloride and then stirred for 15 minutes. Then at 50-60 of a total of 20.5 ml of propargyl bromide are added so much solvent until the reaction starts and the temperature rises to 70; then the remaining propargyl bromide, diluted with 35 ml of abs. Benzene, added.
The mixture is stirred for 30 minutes. Then at 20-25 50 g of 1- (ss-phenyl-ethyl) -4-piperidone in 150 ml of abs. Benzene was added dropwise with ice cooling and the mixture was stirred for a further 15 hours. Then the reaction mixture is concentrated with about 150 g of ice and 150 ml. Hydrochloric acid decomposed and the benzene phase separated. b) The hydrochloric acid solution obtained is stirred for 4-6 hours at 40-60. Then it is washed with chloroform, with conc. Sodium hydroxide solution made alkaline and extracted with chloroform.
The chloroform solution is dried and evaporated and the residue is distilled, the 1- [1'- (-phenyl-ethyl) -4'-hydroxy-4'-piperidyl] -
2-propanone of bp o, oi 135-140 is obtained.
Analogously to the procedure of Example 1 or 2, z. B. the following compounds can also be obtained:
1- (1'-Merthyl-4'-hdyroxy'-4-piperidyl) -2-butanone,
B.p. 0195, citrate m.p. 145-146; 1- (1'-methyl-4'-hydroxy-4'-piperidyl) -2-pentanone, KP. o, oos 119-121, citrate m.p. 126-128;
1- (1'-methyl-4'-hydroxy-4'-piperidyl) -2-hexanone, b.p. o, or 11g118;
1- (1'-methyl-4'-hydroxy-4'-piperidyl) -3-phneyl
2-propanone, b.p. 0.003 132-135;
2- (1'-methyl-4'-hydroxy-4'-piperidyl) -3-pentanone,
B.p. 008 95-100, citrate 130-132;
1- (1'-n-propyl-4'-hydroxy-4'-piperidyl)
2-propanone, bp. 0180-82, hydrochloride
137-139.
Example 3 a) 12 g of finely powdered hydrochloride of 4-piperidinol are added to 20 g of finely powdered sodium hydroxide in 80 ml of chloroform at −20.
Then 2 ml of water are slowly added, whereupon the temperature rises. Cooling ensures that it does not rise above 10.
Sodium sulfate is then added, the reaction mixture is filtered and the filtrate is evaporated in a rotary evaporator, finally for 5 minutes under high vacuum, the 4-piperidinol remaining behind. 9 g of magnesium are in 20 ml of abs. Submitted ether, 0.1 g of mercury chloride added and at -10 to -5 44.5 g of propargyl bromide in 100 ml of abs. Ether added dropwise. The mixture is then stirred for a further 20 minutes at -5. At -5 to 0, 28.95 g of 4-piperidinol in 250 ml of abs.
Benzene was added dropwise, the reaction mixture heating up. Stirring is continued for 30 minutes at 0 and then for about 14 hours at room temperature. Ice and glacial acetic acid are then added, the benzene phase is separated off and extracted with 2N acetic acid. The acetic acid solutions are combined, shaken with ether and then made alkaline.
The liberated base is extracted with chloroform, the chloroform solution is dried and evaporated, whereby 9.3 g of an oil remain. The distillation gives a 61 of bp 0.05 100-140 (air bath) which crystallizes. The 4- (2'-propynyl) -4-piperidinol thus obtained melts at 76-78. b) 1.6 g of the product from a) are left to stand for 3 hours at room temperature with 16 ml of 2N sulfuric acid and 200 mg of mercury sulfate. The reaction mixture is made alkaline and extracted with chloroform, the chloroform solution is dried and evaporated.
The residue is distilled in a bulb tube, whereby 1- (4'-hydroxy 4'-piperidyl) -2-propanone is obtained, boiling point 70, melting point 98-100.
Example 4 a) In a sulphonation flask, 15.35 g of 4-peridone hydrate hydrochloride are dissolved in 110 ml of sodium bicarbonate solution. While cooling and vibrating, 17.1 g of benzyloxycarbonyl chloride and 110 ml of sodium bicarbonate solution are added dropwise at 5-10, so that the reaction mixture always remains alkaline. It is then vibrated for a further 1 hour and the resulting milky emulsion is extracted with ether. The ether solution is shaken twice with 2N hydrochloric acid and then twice with saturated sodium chloride solution, dried and evaporated and the residue is distilled in a high vacuum.
The 1-benzyloxycarbonyl-4-piperidone boils at 125-131 / 0.004 torr. b) 4 g of magnesium in 6 ml of abs. Submitted ether and then with stirring between 10-15 19.5 g of propargyl bromide in 35 ml of abs. Ether added dropwise. Then 19.1 g of 1-benzyloxycarbonyl-4-piperidone in 80 ml of abs. Benzene was slowly added dropwise at 2U-25, forming a lump which, however, dissolves again on further stirring. The reaction mixture is then stirred for a further 3 hours. Then it is decomposed with ice and 2N sulfuric acid and extracted with ether.
The ether solution is shaken well with 2N sulfuric acid, dried and evaporated. The remaining 1-benzyloxycarbonyl-4- (2'-propynyl) + piperidinol boils at 160-163 / 0.01 torr. c) 50 g of 1-benzyloxycarbonyl-4- (2'-propynyl) -4 piperidinol are heated to 35-40 for 1 hour in a mixture of 500 ml of 20% sulfuric acid and 350 ml of dioxane, which contains 5 g of mercury sulfate. The dioxane is then evaporated off in vacuo, the residue is extracted with chloroform, the chloroform extract is washed with saturated sodium chloride solution, dried and evaporated.
The distillation of the residue gives this
1- (1'-Benzyloxycarbonyl-4'-hydroxy-4'-piperidyl)
2-propanone of bp. 03 180-190 C. d) 30.8 g of (1- (1'-benzyloxycarbonyl-4'-hydroxy-4 'piperidyl) -2-propanone are dissolved in 350 ml of ethanol and dissolved in In the presence of 3 g and later a further 1.5 g of 5% palladium-on-carbon hydrogen passed through until no more carbon dioxide can be detected (about 5 hours). Then the catalyst is filtered off, the solution evaporated, the residue taken up in methylene chloride, the solution dried The 1- (4'-hydroxy-4'-piperidyl) -2-propanone goes below 0.01 Torr at 80-100 air bath temperature with partial decomposition above m.p. 98-100, cf. Example 3.
Claims (1)
Priority Applications (42)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL124853D NL124853C (en) | 1963-07-19 | ||
| CH932463A CH426808A (en) | 1963-07-26 | 1963-07-26 | Process for the preparation of new piperidine derivatives |
| US382955A US3366638A (en) | 1963-07-19 | 1964-07-15 | 1-(1'-hydrocarbyl substituted-4'-hydroxy-4'-piperidyl)-2-ketones |
| BE650736D BE650736A (en) | 1963-07-19 | 1964-07-17 | |
| DE19641445838 DE1445838A1 (en) | 1963-07-19 | 1964-07-17 | New piperidine derivatives and processes for their preparation |
| BE650737D BE650737A (en) | 1963-07-19 | 1964-07-17 | |
| DE19641445837 DE1445837A1 (en) | 1963-07-19 | 1964-07-17 | Process for the preparation of new piperidine derivatives |
| NL6408219A NL6408219A (en) | 1963-07-19 | 1964-07-17 | |
| BE650738D BE650738A (en) | 1963-07-19 | 1964-07-17 | |
| NL6408218A NL6408218A (en) | 1963-07-19 | 1964-07-17 | |
| AT629365A AT255420B (en) | 1963-07-26 | 1964-07-17 | Process for the preparation of new piperidine derivatives |
| DE19641445836 DE1445836A1 (en) | 1963-07-19 | 1964-07-17 | Process for the preparation of new derivatives of 1,2,3,6-tetrahydropyridine |
| NL6408223A NL6408223A (en) | 1963-07-19 | 1964-07-17 | |
| FR982319A FR1415585A (en) | 1963-07-19 | 1964-07-20 | New piperidine derivatives and their preparation |
| FR982320A FR1414820A (en) | 1963-07-19 | 1964-07-20 | New derivatives of 1, 2, 3, 6-tetrahydro-pyridine and their preparation |
| FR982318A FR1423686A (en) | 1963-07-19 | 1964-07-20 | Piperidine derivatives and their preparation |
| ES0302394A ES302394A1 (en) | 1963-07-26 | 1964-07-24 | Procedure for the preparation of new derivatives of piperidine. (Machine-translation by Google Translate, not legally binding) |
| GB30575/64A GB1062714A (en) | 1963-07-19 | 1964-08-04 | -ß-(4'-acyloxy-4'-piperidyl)-ketones |
| GB30577/64A GB1062715A (en) | 1963-07-19 | 1964-08-04 | -ß-(4'-tetrahydropyridyl)-ketones |
| GB30574/64A GB1062713A (en) | 1963-07-19 | 1964-08-04 | 4'-hydroxy-4'-piperidyl-ketones |
| FR991815A FR3759M (en) | 1963-07-19 | 1964-10-17 | Medicinal product based on new piperidine derivatives, having in particular analgesic and anti-coughing action. |
| FR991817A FR3662M (en) | 1963-07-19 | 1964-10-17 | Medicinal product based on new 1.2.3.6-tetrahydropyridine derivatives, having in particular analgesic and anti-cough properties. |
| FR991816A FR3760M (en) | 1963-07-19 | 1964-10-17 | Medicinal product based on 1.2.3.6-tetrahydropyridine derivatives, having in particular analgesic and anti-cough properties. |
| FI00066/66A FI46846B (en) | 1963-07-19 | 1966-01-11 | |
| US520093A US3408357A (en) | 1963-07-19 | 1966-01-12 | Alkyl acid esters of 4-alkyloxy-n-substituted-4-piperidinols |
| BR176431/66A BR6676431D0 (en) | 1963-07-19 | 1966-01-14 | PROCESS TO PRODUCE NEW PIPERIDINIC DERIVATIVES |
| GB1774/66A GB1116326A (en) | 1963-07-19 | 1966-01-14 | Piperidine derivatives and processes for their production |
| IL24971A IL24971A (en) | 1963-07-19 | 1966-01-14 | Piperidine derivatives and their preparation |
| DK20266AA DK114973B (en) | 1963-07-19 | 1966-01-14 | Process for the preparation of piperidine derivatives or salts thereof. |
| NL6600523A NL6600523A (en) | 1963-07-19 | 1966-01-14 | |
| BE675145D BE675145A (en) | 1963-07-19 | 1966-01-14 | |
| DE19661695054 DE1695054A1 (en) | 1963-07-19 | 1966-01-14 | Process for the preparation of new piperidine derivatives |
| SE00500/66A SE327986B (en) | 1963-07-19 | 1966-01-14 | |
| NO161258A NO121781B (en) | 1963-07-19 | 1966-01-14 | |
| FR46020A FR1463646A (en) | 1963-07-19 | 1966-01-15 | Piperidine derivatives and their preparation |
| FR57638A FR5343M (en) | 1963-07-19 | 1966-04-14 | |
| US562533A US3338910A (en) | 1963-07-19 | 1966-07-05 | Piperidine derivatives of 1-hydrocarbyl-4-alkenylene-isonipecotic acid esters |
| DK104067AA DK114622B (en) | 1963-07-19 | 1967-02-27 | Process for the preparation of piperidine derivatives or salts thereof. |
| US660909A US3456060A (en) | 1963-07-19 | 1967-08-16 | Therapeutic compositions containing piperidine derivatives and methods of treating cough and pain therewith |
| US671549A US3498994A (en) | 1963-07-19 | 1967-09-29 | Certain 1,2,3,6-tetrahydro-4-pyridyl ketones |
| US800012*A US3509258A (en) | 1963-07-19 | 1968-10-11 | Therapeutic compositions containing piperidine derivatives and methods of treating cough therewith |
| MY1971123A MY7100123A (en) | 1963-07-19 | 1971-12-31 | Piperidine derivatives and processes for their production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH932463A CH426808A (en) | 1963-07-26 | 1963-07-26 | Process for the preparation of new piperidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH426808A true CH426808A (en) | 1966-12-31 |
Family
ID=4350753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH932463A CH426808A (en) | 1963-07-19 | 1963-07-26 | Process for the preparation of new piperidine derivatives |
Country Status (3)
| Country | Link |
|---|---|
| AT (1) | AT255420B (en) |
| CH (1) | CH426808A (en) |
| ES (1) | ES302394A1 (en) |
-
1963
- 1963-07-26 CH CH932463A patent/CH426808A/en unknown
-
1964
- 1964-07-17 AT AT629365A patent/AT255420B/en active
- 1964-07-24 ES ES0302394A patent/ES302394A1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT255420B (en) | 1967-07-10 |
| ES302394A1 (en) | 1965-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT389875B (en) | METHOD FOR PRODUCING 4H-1-BENZOPYRAN-4-ON DERIVATIVES, NEW 4H-1-BENZOPYRAN-4-ON DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS | |
| CH624102A5 (en) | ||
| DE1930818B2 (en) | 1-Substituted 3- or 4-aroylpiperidines, process for their preparation and their use | |
| DE2555590A1 (en) | 1-SUBSTITUTED-4-BENZYLIDEN PIPERIDINES AND THE METHOD OF MANUFACTURING THEREOF | |
| DE1445837A1 (en) | Process for the preparation of new piperidine derivatives | |
| DE1518663A1 (en) | Basically substituted cycloalkene derivatives and process for their preparation | |
| DE1670186A1 (en) | Process for the preparation of p-alkoxypiperidine amides | |
| CH426808A (en) | Process for the preparation of new piperidine derivatives | |
| DE1289845B (en) | 4- (4'-Hydroxy-4'-phenylpiperidino) -butyrophenones, their acid addition salts and processes for their preparation | |
| DE2065426C3 (en) | ||
| DE2560602C2 (en) | Oxygenated diarylamidines | |
| CH426809A (en) | Process for the preparation of new derivatives of 1,2,3,6-tetrahydropyridine | |
| AT253510B (en) | Process for the preparation of new piperidine derivatives | |
| AT203002B (en) | Process for the preparation of new, heterocyclically substituted pyrazolone derivatives | |
| AT252917B (en) | Process for the preparation of new derivatives of 1,2,3,6-tetrahydropyridine | |
| DE939207C (en) | Process for the preparation of basic substituted fatty acid (2-chloro-6-methyl-anilides) and their salts which can be used as local anesthetics | |
| AT252215B (en) | Process for the preparation of new substituted 1-phenyl-2-isopropylaminoethanols and their salts | |
| AT360016B (en) | METHOD FOR PRODUCING THE NEW 1-METHYL-4- (3-CARBOXY-10,11-DIHYDRO-5H-DIBENZO- (A, D) - CYCLOHEPTEN-5-YLIDEN) -PIPERIDINE (10,11-DIHYDRO- -3- CARBOXY-CYPROHEPTADINE), HIS N-OXIDS AND HIS SALTS | |
| AT238182B (en) | Process for the preparation of new pyrrolidine compounds | |
| DE2104312C3 (en) | (α, α, β, β-tetrafluorophenethyl) -α, α-dimethylbenzylamine derivatives, processes for their preparation and medicaments containing them | |
| CH447163A (en) | Process for the preparation of new piperidine derivatives | |
| AT238184B (en) | Process for the preparation of new pyrrolidine compounds | |
| AT395712B (en) | Process for the preparation of novel alkyl (1-((2- phenoxyethyl)amino)propylidene)hydrazinecarboxylates | |
| AT360017B (en) | METHOD FOR PRODUCING THE NEW 1-METHYL-4- (3-CARBOXY-10,11-DIHYDRO-5H-DIBENZO- (A, D) - -CYCLOHEPTEN-5-YLIDEN) -PIPERIDINE (10,11-DIHYDRO -3- CARBOXY-CYPROHEPTADINE), HIS N-OXIDS AND HIS SALTS | |
| AT275518B (en) | Process for the preparation of new 1- (4-oxo-4-phenyl-butyl) -piperidines substituted in the 4-position and of their acid addition salts |